ArticleGene therapy2000
A versatile system for receptor-mediated gene delivery permits increased entry of DNA into target cells, enhanced delivery to the nucleus and elevated rates of transgene expression.
Article in Gene therapy, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Efficient Messenger RNA Delivery to the Kidney Using Renal Pelvis Injection in Mice.Pharmaceutics · 2021Article
- Optimization of Tet1 ligand density in HPMA-co-oligolysine copolymers for targeted neuronal gene delivery.Biomaterials · 2013Article
- Relationships between liposome properties, cell membrane binding, intracellular processing, and intracellular bioavailability.The AAPS journal · 2011Article
- AAV's anatomy: roadmap for optimizing vectors for translational success.Current gene therapy · 2010Article
- Biophysical characterization of copolymer-protected gene vectors.Biomacromolecules · 2010Article
- The silent (R)evolution of polymeric nucleic acid therapeutics.Pharmaceutical research · 2008Article
- Multifunctional nanoparticulate polyelectrolyte complexes.Pharmaceutical research · 2007Review
- Kinetic analysis of nanoparticulate polyelectrolyte complex interactions with endothelial cells.Biomaterials · 2007Article
- Use of synthetic vectors for neutralising antibody resistant delivery of replicating adenovirus DNA.Gene therapy · 2006Article
- Transfection efficiency of pORF lacZ plasmid lipopolyplex to hepatocytes and hepatoma cells.World journal of gastroenterology · 2004Article
- Enhancing polyethylenimine's delivery of plasmid DNA into mammalian cells.Proceedings of the National Academy of Sciences of the United States of America · 2002Article
- Intracellular rate-limiting steps of gene transfer using glycosylated polylysines in cystic fibrosis airway epithelial cells.Gene therapy · 2002Article
- Nonviral gene transfer strategies for the vasculature.Microcirculation (New York, N.Y. : 1994) · 2002Review
- Peptide-mediated RNA delivery: a novel approach for enhanced transfection of primary and post-mitotic cells.Nucleic acids research · 2001Article
- Triggered intracellular activation of disulfide crosslinked polyelectrolyte gene delivery complexes with extended systemic circulation in vivo.Gene therapy · 2001Article
- Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies.Gene therapy · 2001Article
- Nucleic acid vaccines: tasks and tactics.Immunologic research · 2001Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have developed a method for stabilisation of polyelectrolyte gene delivery vectors by crosslinking their surfaces with biodegradable multivalent copolymers based on N-(2-hydroxypropyl)methacrylamide (HPMA). The resulting nanoparticulate vectors resist attack by serum proteins and can be modified for cell-specific delivery by incorporation of targeting ligands onto the polymer coating. Here we show that vascular endothelial growth factor (VEGF), transferrin and basic fibroblast growth factor (bFGF) can each be linked to polyHPMA-coated poly(L-lysine)/DNA complexes. All ligand-targeted complexes demonstrated increased uptake into receptor-positive cells (measured using plasmids containing 32P-dCTP), that could be antagonised with excess free ligand. Targeted complexes also showed increased transfection, resistant to inhibition by serum, suggesting the possibility of effective application in vivo. Analysis using fluorescence microscopy confirmed enhanced uptake of ligand-targeted complexes (using Texas Red-labelled plasmid DNA), although VEGF- and transferrin-targeted complexes were restricted to cytoplasmic or perinuclear distributions. In contrast, bFGF-targeted complexes showed efficient delivery into the nucleus, with accumulation of more than 100000 plasmids per cell within distinct intranuclear compartments. This method permits versatile targeting of genes to selected cells and may also permit manipulation of intracellular trafficking. It should find several important applications in gene delivery systems both in vitro and in vivo.
Indexed as
Identifiers
10918506What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.